PHILADELPHIA, PA, June 03, 2011 (Press-News.org) Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.
The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.
The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-in-class drugs, like NKP-1339, can take us one step further to address this high unmet need." While Dr. Burris commented, "The results to date indicate that NKP-1339 could be a promising new agent that would enhance our anti-cancer armamentarium."
About Niiki Pharma
Niiki Pharma Inc. is an oncology therapeutics development company with a pipeline of novel targeted anti-cancer agents. For more information, visit http://www.niikipharma.com
About Translational Genomics Institute
The Translational Genomics Research Institute (TGen) is dedicated to conducting groundbreaking research with diseases such as cancer, neurological disorders and diabetes. For more information, visit http://www.tgen.org.
About Sarah Canon Research Institute
Sarah Cannon Research Institute (SCRI) is a global clinical research organization focusing on advancing therapies and accelerating drug development in areas such as oncology, cardiology and gastroenterology. For more information, visit http://www.sarahcanonresearch.com.
CONTACT: For media relations and other inquiries: Carolyn Rhinebarger, carolyn@luminovas.com, +1-919-604-4053; For investor relations: Ali Ardakani, ardakani@niikipharma.com, +1-201-238-2885
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Niiki Pharma will present Phase I clinical study data for its transferrin targeted ruthenium based anti-cancer compound, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.
2011-06-03
ELSE PRESS RELEASES FROM THIS DATE:
Sun Dental Labs' Custom Implant Abutments Named Top 25 Product By Dentistry Today
2011-06-03
Sun Dental Labs - a full-service dental laboratory serving dentists and dental labs worldwide - has had their Suntech custom implant abutments named to Dentistry Today Magazine's Top 25 Implant Products for 2011.
SunTech Implant Abutments come in titanium, zirconia and hybrid materials. They are platform independent and are available for all major implant systems, including 3i - Astra, Nobelbiocare Branemark, Nobelbiocare Replace, Zimmer & BioHorizons.
The advantage of restoring an implant with a custom abutment is that dentists get the optimal design and control ...
TutorFi.com Online Tutoring Embraces a Bright Future of Growing Children
2011-06-03
When it comes to premiere Educational Online Tutoring - TutorFi.com has options. Parents and Students would probably be motivated for they offer K-12 Tutors, at anytime for your child.Actual teaching in the classroom really great. In Online Tutoring it helps more on what a classroom teaching can offer. We tend to boost your child grades to especially help her homework assignments done and even take a review for the future test and lessons. Consider these step to improve more in which an Online Tutoring Service can offer.
1. Study Plan - Every Online Tutors always focus ...
Camp Bow Wow Announces 2011 First Quarter Golden Paw and Golden Wags + Whiskers Winners
2011-06-03
Camp Bow Wow, the nation's largest pet services company, announces the six recipients of its Golden Paw Awards and one recipient of its Wag + Whiskers Award for the first quarter of the 2011 fiscal year.
The Golden Paw Award honors Camp Bow Wow locations based on safety, service, and success. Six winners were chosen out of 200+ camp locations throughout the country. Winning camps set the bar for leading safety standards, top percentage revenue, along with philanthropic support for the Bow Wow Buddies Foundation. The Golden Wags + Whiskers Award recognizes one Home Buddies ...
Hepatitis B Foundation Breaks Fundraising Record at 20th Anniversary Crystal Ball
2011-06-03
On May 13, 2011, the Hepatitis B Foundation hosted its 20th Anniversary Crystal Ball fundraiser at PineCrest Country Club in Lansdale, Pa. With the highest attendance to-date, nearly 260 leaders from the community, academia, corporations, government, and biotech gathered to support the Foundation. The benefit raised $95,000 to advance the Foundation's mission of eliminating hepatitis B worldwide.
When addressing the Crystal Ball attendees, Foundation Board Chairman Joel Rosen, Esq. honored the memory of Nobel Laureate and Hepatitis B Foundation Co-founder and Distinguished ...
Luxury 'No Rain Guaranteed' Break at Cameron House Hotel
2011-06-03
Cameron House on the "Sunny, Sunny Banks of Loch Lomond" has created a luxury 'No Rain Guaranteed' package in order to offer holidaymakers a reason to staycation this summer, rather than going abroad for their sunshine.
To combat Scotland's reputation as a damp and drizzly destination, Cameron House will guarantee a rain free experience during stays in the opulent Whisky Suites or guests enjoy a complimentary one night stay on their next visit.
During the stay guests enjoy the signature treatment in the hotel's Carrick Spa - The Rainshower Ritual. Guaranteed ...
Legacy Trust Award Collection Announces Winners
2011-06-03
The votes are in - and Josh Andrus, Elaine Hoogeboom and Michael Johnson are the three top winners of the Second Annual Legacy Trust Award Collection.
Public voting wrapped up May 20th in the competition for adult artists with disabilities, which is co-sponsored by Legacy Trust and VSA Michigan-Grand Rapids. Each Legacy Trust Award Collection winner received a cash prize and will be entered in ArtPrize 2011. Hoogeboom was one of the top vote-getters in the 2010 LTAC competition.
"We were very pleased to once again partner with VSA Michigan-Grand Rapids to host ...
Know What You'll Need After Divorce
2011-06-03
Know What You'll Need After Divorce
During a divorce, couples are doing more than ending an emotional relationship. In the midst of deciding who gets what, their asset splitting is really financial planning in disguise. Negotiations regarding child care, child support, insurance, retirement accounts and even joint credit cards and loans come into the picture. These decisions can impact a person's future financial stability. So it is wise to pre-plan and weigh financial needs before entering into a separation or settlement agreement.
Life after divorce could entail ...
Helping Children Understand Divorce
2011-06-03
Helping Children Understand Divorce
When a marriage ends, the breakup is generally about more than just lost love. Financial issues, fidelity, or communication breakdowns may have played a part; however, when children are part of the equation, divorce signals change, and is a complicated concept to explain and sometimes to understand for a child. As a result, parents must take particular care when trying to help their child understand and ultimately cope with changes in their family.
Divorce causes stress for children because of the various elements of uncertainty. ...
New IMS Service from Lambda Calibration
2011-06-03
Lambda Calibration Ltd, the Chorley based UKAS calibration laboratory are pleased to announce their new Inventory Management Solution.
The Inventory Management Solution (IMS) enables clients to have free web access to their measuring equipment calibration records. The client can generate "recall" and "overdue" reports and even export the measuring equipment inventory to a spreadsheet. Calibration certificates can be downloaded, viewed or printed calibration certificates. Simple and easy to use, this new Inventory Management Solution has already been ...
Former Wall Street Executive Reveals Top Strategic Business Consulting Methods
2011-06-03
A wise way of accomplishing a top position in business is through business coaching, because it renders effective strategies to reap a successful harvest in the businesses. Former Wall Street Executive reveals top strategic business consulting ( http://www.rmcstrategies.com ) methods that have more hands-on approach to assisting business owners and managers with solving challenges in their business as well as general coaching advice.
Business consulting is one of the biggest assets for small business owner. Not just because of the money invested, but the hard work and ...
LAST 30 PRESS RELEASES:
Canada’s fastest academic supercomputer is now online at SFU after $80m upgrades
Architecture’s past holds the key to sustainable future
Laser correction for short-sightedness is safe and effective for older teenagers
About one in five people taking Ozempic, Wegovy or Mounjaro say food tastes saltier or sweeter than before
Taking semaglutide turns down food noise, research suggests
Type 2 diabetes may double risk of sepsis, large community-based study suggests
New quantum sensors can withstand extreme pressure
Tirzepatide more cost-effective than semaglutide in patients with knee osteoarthritis and obesity
GLP-1 drugs shown cost-effective for knee osteoarthritis and obesity
Interactive apps, AI chatbots promote playfulness, reduce privacy concerns
How NIL boosts college football’s competitive balance
Moffitt researchers develop machine learning model to predict urgent care visits for lung cancer patients
Construction secrets of honeybees: Study reveals how bees build hives in tricky spots
Wheat disease losses total $2.9 billion across the United States and Canada between 2018 and 2021
New funding fuels development of first potentially regenerative treatment for multiple sclerosis
NJIT student–faculty team wins best presentation award for ant swarm simulation
Ants defend plants from herbivores but can hinder pollination
When the wireless data runs dry
Inquiry into the history of science shows an early “inherence” bias
Picky eaters endure: Ecologists use DNA to explore diet breadth of wild herbivores
Study suggests most Americans would be healthier without daylight saving time
Increasing the level of the protein PI31 demonstrates neuroprotective effects in mice
Multi-energy X-ray curved surface imaging-with multi-layer in-situ grown scintillators
Metasurface enables compact and high-sensitivity atomic magnetometer
PFAS presence confirmed in the blood of children in Gipuzkoa
Why do people believe lies?
SwRI installs private 5G network for research, development, testing and evaluation
A new perspective in bone metabolism: Targeting the lysosome–iron–mitochondria axis for osteoclast regulation
Few military spouses use formal support services during, after deployment
Breakthrough in the hunt for light dark matter: QROCODILE project reveals world-leading constraints
[Press-News.org] Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I ResultsNiiki Pharma will present Phase I clinical study data for its transferrin targeted ruthenium based anti-cancer compound, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.